Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
Background: Hemolytic uremic syndrome (HUS) is rare in neonates. It is probably an under-recognized condition in the early postnatal period as it presents similarly to the most common perinatal asphyxia and to differentiate the two conditions is challenging. We describe the clinical presentation of...
Saved in:
Main Authors: | Dorottya Kelen (Author), Benedetta Chiodini (Author), Valérie Godart (Author), Brigitte Adams (Author), Patrick Stordeur (Author), Khalid Ismaili (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
by: Jacob H. Umscheid, et al.
Published: (2021) -
Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
by: Stefanie W. Benoit, et al.
Published: (2022) -
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
by: Halka K, et al.
Published: (2011) -
Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1
by: Benedetta Chiodini, et al.
Published: (2022) -
PREVENTION OF SEVERE INFECTIONS IN PATIENTS WITH GENETIC DISORDERS OF THE COMPLEMENT SYSTEM REGULATION TREATING WITH ECULIZUMAB: PRESS RELEASE ON THE INTERDISCIPLINARY EXPERT COUNCIL MEETING
by: Editorial article
Published: (2017)